Emergent BioSolutions Secures Exclusive Rights to KLOXXADO in U.S. and Canada

• Emergent BioSolutions has obtained exclusive rights to distribute KLOXXADO Nasal Spray in the U.S. and Canada through a six-year agreement with Hikma Pharmaceuticals.

• The addition of this 8 mg naloxone spray strengthens Emergent’s portfolio in combating the opioid crisis.

Emergent BioSolutions, a leading biopharmaceutical company, has announced an exclusive six-year agreement with Hikma Pharmaceuticals to distribute KLOXXADO Nasal Spray in the United States and Canada. This high-dose, 8 mg naloxone hydrochloride spray is approved for emergency treatment of known or suspected opioid overdoses.

The agreement builds on Emergent’s commitment to addressing the opioid epidemic by complementing its existing NARCAN Nasal Spray, which offers a 4 mg dose. By introducing KLOXXADO to its portfolio, the company now provides healthcare providers, law enforcement, and harm reduction groups with tailored options for overdose reversal treatments.

Joe Papa, President and CEO of Emergent, emphasised the company’s dedication, stating, “Meeting the needs of our patients and customers by now offering two nasal naloxone products at different strengths allows Emergent to do its part to help save lives from this devastating crisis.”

KLOXXADO will remain manufactured by Hikma Pharmaceuticals and will be distributed through Emergent’s extensive channels, including its NARCANDirect online platform. This integration will facilitate bulk purchases by emergency medical services, government agencies, and community programs.